Patents Examined by Yong Chu
  • Patent number: 7541372
    Abstract: The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein R1, R2, and R3, are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. This class of compounds has high affinity and selectivity for GABA A ?5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: June 2, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Andreas Koblet, Andrew Thomas
  • Patent number: 7541485
    Abstract: The present invention relates to novel methods for the preparation of glutamic acid derivatives and intermediates thereof, and such compounds prepared by the novel methods.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: June 2, 2009
    Assignee: Wyeth
    Inventors: Ronald S. Michalak, Joseph Zeldis, Mel Jennings, David M. Blum, Timothy Doyle
  • Patent number: 7534791
    Abstract: The present invention relates to benzo[b]furane and benzo[b]thiophene derivatives of the general formula IV as the free base or salts thereof and their use.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: May 19, 2009
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Morten Bang Norgaard
  • Patent number: 7531568
    Abstract: Compounds are described that are active on at least one of PPAR?, PPAR?, and PPAR?, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR?, PPAR?, and PPAR?.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: May 12, 2009
    Assignee: Plexxikon, Inc.
    Inventors: Jack Lin, Dean R. Artis, Prabha N. Ibrahim, Chao Zhang, Rebecca Zuckerman, Ryan Bremer, Shenghua Shi, Byunghun Lee
  • Patent number: 7527652
    Abstract: Mixtures of (A) from 55 to 65 mol % of erythro-dithiol of formula erythro-IV: and (B) from 35 to 45 mol % of threo-dithiol of formula threo-IV or threo-IV?: and their corresponding alkali metal salts and ammonium salts, are useful for treating animal hides.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: May 5, 2009
    Assignee: BASF Aktiengesellschaft
    Inventors: Holger Buehler, Joaquim Henrique Teles, Gunther Pabst, Tilman Luedecke Taeger
  • Patent number: 7517884
    Abstract: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: April 14, 2009
    Assignee: Kalypsys Inc.
    Inventors: James W. Malecha, Sergio G. Duron, Andrew K. Lindstrom
  • Patent number: 7517901
    Abstract: Compounds of formula Ia or Ib: wherein X and Y are nitrogen or CRe, and R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds for treatment of p38-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: April 14, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Tobias Gabriel, Michael Soth
  • Patent number: 7514457
    Abstract: Compounds of the general formula (I): pharmaceutical compositions comprising a compound of general formula (I); and methods of treating disease conditions caused by overactivation of the VR1 receptor by administering a compound of general formula (I) to a subject.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: April 7, 2009
    Assignee: Pfizer Inc.
    Inventors: Tadashi Inoue, Satoshi Nagayama, Yuji Shishido
  • Patent number: 7514460
    Abstract: The present invention relates to N2-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: April 7, 2009
    Assignee: 4SC AG
    Inventors: Thomas Herz, Rolf Krauss, Michael Kubbutat, Martin Lang, Christoph Schaechtele, Stefan Tasler, Frank Totzke
  • Patent number: 7514439
    Abstract: The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R1 and R2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R3 and R4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: April 7, 2009
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kazutoshi Sugawara, Tetsuji Matsudaira, Hiroshi Sugama, Masao Nawano, Rikiya Ohashi
  • Patent number: 7514266
    Abstract: Synthetic receptor cores are provided that comprise a compound represented by the following formula: wherein R1, R2, and R3 independently comprise at least one moiety chosen from a hydroxyl group, an amine group, and derivatives thereof. Synthetic receptor cores are provided that comprise a compound represented by the following formula: wherein R comprises at least one moiety chosen from a hydroxyl group, an amine group, and derivatives thereof. Synthetic receptors are provided that comprise a synthetic receptor core; and an analyte binding moiety, wherein the analyte binding moiety is capable of complexion with an analyte. Systems, methods, and kits are also provided that use a synthetic receptor.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: April 7, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Eric V. Anslyn, Aaron T. Wright, Zhenlin Zhong
  • Patent number: 7514463
    Abstract: Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: April 7, 2009
    Assignees: University of Kansas, University of Kansas Medical Center
    Inventors: Gunda I. Georg, Joseph S. Tash, Ramappa Chakrasali, Sudhakar Rao Jakkaraj
  • Patent number: 7498355
    Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: March 3, 2009
    Assignee: Antibe Therapeutics Inc.
    Inventors: John L. Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci
  • Patent number: 7498356
    Abstract: Disclosed are compound and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compound of the invention include inhibitors of protein tyrosine phosphatase, in particular protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising aforementioned conditions using such compounds.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: March 3, 2009
    Assignee: The Institutes for Pharmaceutical Discovery LLC
    Inventors: Darren Whitehouse, Shaojing Hu, Michael C. Van Zandt, Garrett Parker
  • Patent number: 7494999
    Abstract: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: February 24, 2009
    Assignee: Kalypsys, Inc
    Inventors: Stewart A. Noble, Guy Oshiro, James W. Malecha, Cunxiang Zhao, Carmen Robinson, Sergio G. Duron, Michael Sertic, Andrew K. Lindstrom, Andrew K. Shiau, Christopher D. Bayne, Mehmet Kahraman, Boliang Lou, Steven P. Govek
  • Patent number: 7488830
    Abstract: A polymer that includes at least one monomeric unit having a pendant substituent group according to formula (II): wherein: R1 is H, chloro, bromo, alkyl, hydroxyalkyl, aryl, or aralkyl, R2 and R3 are each independently H, alkyl, hydroxyalkyl, aryl, aralkyl, uriedo, or carboxyalkylene, R4 is alkylene or R5, R7, and R10 are each independently alkylene, R6, R8, and R9 are each independently H or alkyl, A is O or N—R11, provided if A is O and R4 is methylene, then R1 cannot be H, chloro, or bromo, R11 is H or alkyl, and X? is an anion, is useful in personal care application, such as hair styling compositions.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: February 10, 2009
    Assignee: Rhodia Inc.
    Inventors: Krishnamurthy Shanmuganandamurthy, Euen Gunn, Stewart Alexander Warburton
  • Patent number: 7485732
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: February 3, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Shouwu Miao, Kathleen M. Rupprecht
  • Patent number: 7485751
    Abstract: The invention is directed at a new process for the preparation of pure enantiomers from the racemate of amidoacetonitrile compounds of formula wherein R1, R2 and R3, independently of each other, signify hydrogen, halogen, nitro, cyano, C1-C6-alkyl, halogen-C1-C6-alkyl, C1-C6-alkoxy, halogen-C1-C6-alkoxy, C2-C6-alkenyl, halogen-C2-C6-alkenyl, C2-C6-alkinyl, halogen-C2-C6-alkinyl, C2-C6-alkenyloxy, halogen-C2-C6-alkenyloxy, C1-C6-alkylthio, halogen-C1-C6-alkylthio, C1-C6-alkylsulfonyloxy, halogen-C1-C6-alkylsulfonyloxy, C1-C6-alkylsulfinyl, halogen-C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, halogen-C1-C6-alkylsulfonyl, C1-C6-alkenylthio, halogen-C1-C6-alkenylthio, C1-C6-alkenylsulfinyl, halogen-C1-C6-alkenylsulfinyl, C1-C6-alkenylsulfonyl, halogen-C1-C6-alkenylsulfonyl, C1-C6-alkylamino, di-(C1-C6-alkyl)amino, C1-C6-alkylaminocarbonyl, di-(C1-C6-alkyl)aminocarbonyl, C1-C6-alkylsulfonylamino, halogen-C1-C6-alkylsulfonylamino, C1-C6-alkylcarbonyl, halogen-C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, unsubstitut
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: February 3, 2009
    Assignee: Novartis Animal Health US, Inc.
    Inventors: Pierre Ducray, Noelle Gauvry, Thomas Goebel, Francois Pautrat
  • Patent number: 7482494
    Abstract: The present invention provides a benzene derivative having a long, linear conjugated structure, the benzene derivative being capable of exhibiting a satisfactory ability to transport charge without photoexcitation, a process for producing the benzene derivative, and a liquid-crystal material and a charge-transport material containing the benzene derivative having a long, linear conjugated structure. That is, a benzene derivative having a long, linear conjugated structure represented by general formula (1): (wherein R1 represents a methyl group or a hydrogen atom, A represents an alkylene group, —CO—O—(CH2)n—, —C6H4—CH2—, or —CO—).
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: January 27, 2009
    Assignee: Nippon Chemical Industrial Co., Ltd.
    Inventor: Yuichiro Haramoto
  • Patent number: 7479502
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: December 3, 2003
    Date of Patent: January 20, 2009
    Assignee: Pharmacyclics, Inc.
    Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young